111 related articles for article (PubMed ID: 26922775)
21. On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver.
Benetatos L; Vartholomatos G
Ann Hematol; 2016 Oct; 95(10):1571-82. PubMed ID: 26983918
[TBL] [Abstract][Full Text] [Related]
22. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.
Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
Oncotarget; 2016 Apr; 7(16):22103-15. PubMed ID: 26959885
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
Pastore F; Levine RL
Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248
[TBL] [Abstract][Full Text] [Related]
24. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.
Zhang X; Sokol L; Bennett JM; Moscinski LC; List A; Zhang L
Leuk Res; 2016 Apr; 43():18-23. PubMed ID: 26927701
[TBL] [Abstract][Full Text] [Related]
25. Autoimmunity and Inflammation in Myelodysplastic Syndromes.
Wolach O; Stone R
Acta Haematol; 2016; 136(2):108-17. PubMed ID: 27337745
[TBL] [Abstract][Full Text] [Related]
26. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
27. Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study.
Ram R; Gatt M; Merkel D; Helman I; Inbar T; Nagler A; Avivi I; Ofran Y
Ann Hematol; 2017 Apr; 96(4):575-579. PubMed ID: 28058490
[TBL] [Abstract][Full Text] [Related]
28. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia.
Zahid MF; Barraco D; Lasho TL; Finke C; Ketterling RP; Gangat N; Hanson CA; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Jun; 58(6):1488-1493. PubMed ID: 27739921
[No Abstract] [Full Text] [Related]
29. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.
Grignano E; Mekinian A; Braun T; Liozon E; Hamidou M; Decaux O; Puéchal X; Kahn JE; Schoindre Y; Rossignol J; Lortholary O; Lioger B; Hermine O; Park S; Ades L; Montestruc F; Ricard L; Gardin C; Fenaux P; Fain O;
Leuk Res; 2016 Aug; 47():136-41. PubMed ID: 27337291
[TBL] [Abstract][Full Text] [Related]
30. Immune Mechanisms in Myelodysplastic Syndrome.
Glenthøj A; Ørskov AD; Hansen JW; Hadrup SR; O'Connell C; Grønbæk K
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314337
[TBL] [Abstract][Full Text] [Related]
31. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
Garcia-Manero G; Almeida A; Giagounidis A; Platzbecker U; Garcia R; Voso MT; Larsen SR; Valcarcel D; Silverman LR; Skikne B; Santini V
BMC Hematol; 2016; 16():12. PubMed ID: 27148452
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Czerw T; Labopin M; Gorin NC; Giebel S; Blaise D; Meloni G; Pigneux A; Bosi A; Veelken J; Ferrara F; Schaap N; Lemoli RM; Cornelissen JJ; Beohou E; Nagler A; Mohty M
Cancer; 2016 Jun; 122(12):1880-7. PubMed ID: 27018549
[TBL] [Abstract][Full Text] [Related]
33. Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome.
Nováková M; Žaliová M; Suková M; Wlodarski M; Janda A; Froňková E; Campr V; Lejhancová K; Zapletal O; Pospíšilová D; Černá Z; Kuhn T; Švec P; Pelková V; Zemanová Z; Kerndrup G; van den Heuvel-Eibrink M; van der Velden V; Niemeyer C; Kalina T; Trka J; Starý J; Hrušák O; Mejstříková E
Haematologica; 2016 Jun; 101(6):707-16. PubMed ID: 27013649
[TBL] [Abstract][Full Text] [Related]
34. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R; Wells RA; Zhu N; Leitch HA; Nevill TJ; Yee KW; Leber B; Sabloff M; St Hilaire E; Kumar R; Geddes M; Shamy A; Storring J; Kew A; Elemary M; Levitt M; Lenis M; Mamedov A; Zhang L; Rockwood K; Alibhai SM
Br J Haematol; 2016 Jul; 174(1):88-101. PubMed ID: 26991631
[TBL] [Abstract][Full Text] [Related]
35. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
[TBL] [Abstract][Full Text] [Related]
36. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081
[TBL] [Abstract][Full Text] [Related]
37. Novel trial designs for high-risk myelodysplastic syndromes.
Alessandrino EP; Porta MGD
Lancet Oncol; 2016 Apr; 17(4):410-412. PubMed ID: 26968356
[No Abstract] [Full Text] [Related]
38. Azacitidine-Induced Pericarditis: A Case Series.
Newman M; Malla M; Gojo I
Pharmacotherapy; 2016 Apr; 36(4):443-8. PubMed ID: 26940554
[TBL] [Abstract][Full Text] [Related]
39. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
40. Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions.
El Cheikh J; Otrock ZK; Qannus AA; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):304-10. PubMed ID: 26923326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
